Biodexa Pharmaceuticals Plc ADR (BDRX)

$0.87 +0.01 (0.80%)
Market Cap 31.38M
Revenue (ttm) 0.00
Net Income (ttm) -7.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.09
Volume 141,000
Avg Vol 2,694,886
Day's Range N/A - N/A
Shares Out 36.54M
Stochastic %K 30%
Beta 1.17
Analysts Strong Sell
Price Target $18.00

Company Profile

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of familial adenomatous polyposis, non-muscle invasive bladder cancer, and Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes. The company is also developing MTX110, which is currently in Phase I studies...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 29 2048 0180
Address:
1 Caspian Point, Caspian Way, Cardiff, United Kingdom
Jspence0427
Jspence0427 Jul. 7 at 3:39 PM
$BDRX can you do something? Just something? I don’t care up/down, just do something?!
0 · Reply
Jspence0427
Jspence0427 Jul. 7 at 11:39 AM
$BDRX 11 days ago they were testing clinical. Everything now is super secret.
1 · Reply
Jspence0427
Jspence0427 Jul. 7 at 11:38 AM
$BDRX there’s news, but they want you to pay for it everywhere I searched lol
0 · Reply
TraderNice
TraderNice Jul. 2 at 11:12 AM
$BDRX there is no news….it will not reach dollar
1 · Reply
Benjp33
Benjp33 Jul. 1 at 1:08 PM
$BDRX getting ready to run!!!
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:21 AM
$GPUS implementing old $BDRX pop towards pandora friday after hours 2.31 when i said will b issue later and /2.45
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:11 AM
$ROKU need to tether u off the BEUD $BDRX 75 pt pocket for marklets usign your may 29th roku now for crypto shift
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:09 AM
$BDRX tweaking your 75 pt up top for entire markets !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 10:38 AM
$OGEN 7.07 is due to $ENVB blend with $BDRX BEUD old when envb popped rom 2.3-7.07 and stock moving from 4-8.18 soon
2 · Reply
Scoty_D
Scoty_D Jun. 27 at 9:22 PM
$BDRX Sheeeeeet 424 filing .......
1 · Reply
Latest News on BDRX
Results of Annual General Meeting

Jun 27, 2025, 8:30 AM EDT - 10 days ago

Results of Annual General Meeting

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Jun 25, 2025, 8:30 AM EDT - 12 days ago

Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Jun 23, 2025, 8:30 AM EDT - 14 days ago

Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Jun 18, 2025, 7:00 AM EDT - 19 days ago

Biodexa Hits Key Milestone For Its Type 1 Diabetes Candidate Tolimidone, Enrolls First Patient In Phase 2a Study

Result of General Meeting

Jun 11, 2025, 4:30 PM EDT - 26 days ago

Result of General Meeting

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Jun 4, 2025, 8:30 AM EDT - 4 weeks ago

Biodexa Announces Recruitment of First Patient in Phase 2 Study of Tolimidone in Type 1 Diabetes

Shareholder Update

May 30, 2025, 8:30 AM EDT - 5 weeks ago

Shareholder Update

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

May 22, 2025, 4:30 PM EDT - 6 weeks ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

May 22, 2025, 8:30 AM EDT - 6 weeks ago

Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

May 12, 2025, 8:30 AM EDT - 2 months ago

Biodexa Receives Orphan Drug Designation in Europe for eRapa in FAP

Notice of General Meeting

Apr 17, 2025, 8:30 AM EDT - 2 months ago

Notice of General Meeting

Preliminary Results for the Year Ended 31 December 2024

Apr 11, 2025, 8:30 AM EDT - 3 months ago

Preliminary Results for the Year Ended 31 December 2024

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Mar 19, 2025, 7:00 AM EDT - 3 months ago

With Fast Track Designation in Hand, a Successful Protocol Discussion with FDA, and CROs in Place, Biodexa is on Track to Initiate its Funded Phase 3 Trial in FAP Next Quarter

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Mar 10, 2025, 8:30 AM EDT - 4 months ago

Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Mar 6, 2025, 8:30 AM EST - 4 months ago

Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Feb 24, 2025, 8:30 AM EST - 4 months ago

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Feb 13, 2025, 8:30 AM EST - 5 months ago

Biodexa Pharmaceuticals PLC to Present at the Emerging Growth Conference on February 19, 2025

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Feb 12, 2025, 7:30 AM EST - 5 months ago

Following Positive Phase 2 Results and Orphan Drug Designation, Biodexa's FAP Drug Receives FDA Fast Track Status

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Feb 10, 2025, 8:30 AM EST - 5 months ago

Biodexa Receives US FDA Fast Track Designation for eRapa in Familial Adenomatous Polyposis

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Jan 22, 2025, 8:30 AM EST - 5 months ago

Biodexa Strengthens Management Team - Appointment of Dr Gary A. Shangold as Chief Medical Officer

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Nov 21, 2024, 7:35 AM EST - 8 months ago

Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Nov 12, 2024, 8:48 AM EST - 8 months ago

Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on Nasdaq

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Oct 31, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Shareholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Oct 30, 2024, 10:00 AM EDT - 8 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Biodexa Pharmaceuticals Plc (BDRX) and Encourages Investors to Learn More About the Investigation

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Oct 29, 2024, 10:00 AM EDT - 8 months ago

Biodexa Pharmaceuticals Plc (BDRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Oct 28, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Reach Out

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Oct 27, 2024, 10:00 AM EDT - 9 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Biodexa Pharmaceuticals Plc (BDRX) And Encourages Stockholders to Connect

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Oct 17, 2024, 7:30 AM EDT - 9 months ago

Biodexa's MX-110 Continues to Show Promise in Recurrent Glioblastoma (rGBM), the Deadliest Brain Cancer

Biodexa Announces Successful Appeal of Nasdaq Delisting

Oct 15, 2024, 4:15 PM EDT - 9 months ago

Biodexa Announces Successful Appeal of Nasdaq Delisting

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Oct 4, 2024, 8:30 AM EDT - 9 months ago

Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma

Interim results for the six months ended June 30, 2024

Sep 26, 2024, 8:30 AM EDT - 10 months ago

Interim results for the six months ended June 30, 2024

ADR Ratio Change

Sep 19, 2024, 4:30 PM EDT - 10 months ago

ADR Ratio Change

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Aug 30, 2024, 4:30 PM EDT - 11 months ago

Receipt of Nasdaq Delisting Determination - Plans to Appeal

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 23, 2024, 8:30 AM EDT - 1 year ago

Announces Closing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Jul 19, 2024, 8:30 AM EDT - 1 year ago

Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Jul 11, 2024, 12:44 PM EDT - 1 year ago

Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Jul 11, 2024, 8:30 AM EDT - 1 year ago

Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Jul 2, 2024, 8:30 AM EDT - 1 year ago

Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024

Jspence0427
Jspence0427 Jul. 7 at 3:39 PM
$BDRX can you do something? Just something? I don’t care up/down, just do something?!
0 · Reply
Jspence0427
Jspence0427 Jul. 7 at 11:39 AM
$BDRX 11 days ago they were testing clinical. Everything now is super secret.
1 · Reply
Jspence0427
Jspence0427 Jul. 7 at 11:38 AM
$BDRX there’s news, but they want you to pay for it everywhere I searched lol
0 · Reply
TraderNice
TraderNice Jul. 2 at 11:12 AM
$BDRX there is no news….it will not reach dollar
1 · Reply
Benjp33
Benjp33 Jul. 1 at 1:08 PM
$BDRX getting ready to run!!!
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:21 AM
$GPUS implementing old $BDRX pop towards pandora friday after hours 2.31 when i said will b issue later and /2.45
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:11 AM
$ROKU need to tether u off the BEUD $BDRX 75 pt pocket for marklets usign your may 29th roku now for crypto shift
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 11:09 AM
$BDRX tweaking your 75 pt up top for entire markets !
0 · Reply
Love_To_Learn
Love_To_Learn Jul. 1 at 10:38 AM
$OGEN 7.07 is due to $ENVB blend with $BDRX BEUD old when envb popped rom 2.3-7.07 and stock moving from 4-8.18 soon
2 · Reply
Scoty_D
Scoty_D Jun. 27 at 9:22 PM
$BDRX Sheeeeeet 424 filing .......
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 7:48 PM
$BDRX intraday 0.83 code limit
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 7:30 PM
$WOLF tapped LISA with u $BDRX all other linakges with beloved etc ......
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 7:29 PM
$BDRX 0.83* 0.49 * lisa etc. all binding 0.83 is max dpo intraday on a date that needs to change from after hours etc. migration prior to weekend and next week
0 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 7:29 PM
$IBO $BDRX due to $GNLN all messages apply and stocks tagged ! $SLS
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 7:27 PM
$BDRX due to crypto shift n previous messages on her 0.83 etc........ normal drops
1 · Reply
Love_To_Learn
Love_To_Learn Jun. 27 at 11:02 AM
$BDRX exchanged metadata $IBO
1 · Reply
vaselineguy
vaselineguy Jun. 27 at 3:33 AM
$BDRX the beaud where mo the hungryearner the gridplayer told his followers invest their underpants and now 99.99% money is g9ne. @Love_To_Learn a bad person, ugly human btw he has 2 accounts @joka2189 pretend be another persons who translate his gibberish lmao $AKBA $PSTV
3 · Reply
MCapitalJ
MCapitalJ Jun. 26 at 9:09 PM
$BDRX we not expecting anything here or what?! why so quiet?
1 · Reply
MCapitalJ
MCapitalJ Jun. 26 at 5:27 PM
$BDRX @Love_To_Learn that 0.91 👀🫣
0 · Reply
TraderNice
TraderNice Jun. 26 at 5:02 PM
$BDRX the shorts are covering now look for a leap in price. The stock is now only 10% shorted, the cost to borrow is kicking in…hopefully we can get to 1.00
0 · Reply
MCapitalJ
MCapitalJ Jun. 26 at 1:51 PM
$BDRX 🤝🏼 $VOR ? 🤔👀
1 · Reply
Baseball89
Baseball89 Jun. 26 at 1:04 PM
$BDRX $IMRN ..... This one looks solid. Continue quarterly revenue growth. This one needs some traction. Shares are cheap. US military contract... Travelan
1 · Reply